Lilly says about 700,000 seniors started GLP-1 drugs since Medicare coverage began in July.
Why it matters: The numbers offer an early read on how Medicare policy is reshaping demand in a major obesity-drug market. They also suggest Lilly is capturing most of the initial senior demand.
- Lilly said about 70% of the new senior GLP-1 users are taking its medicines.
- CMS launched the Medicare GLP-1 Bridge on July 1, 2026, at $50 per month for eligible Part D beneficiaries.
- The temporary program runs through December 31, 2027 and operates outside standard Medicare Part D coverage and payment flow.
- Lilly previously said the Bridge expanded U.S. covered lives for its obesity medicines by about 35%.
Eli Lilly said on September 21 that about 700,000 new seniors have started GLP-1 drugs since Medicare coverage began in July, with roughly 70% taking Lilly medicines. The company’s figure is one of the first clear reads on early demand after CMS launched the Medicare GLP-1 Bridge, a short-term demonstration for eligible Medicare Part D beneficiaries.
CMS said the program began on July 1, 2026 and gives eligible beneficiaries access to certain GLP-1 drugs for weight management at $50 per month. The agency said the Bridge will run through December 31, 2027 and operates outside the ordinary Medicare Part D coverage and payment flow. CMS overview
Lilly had already told investors in its second-quarter 2026 materials that the Bridge had expanded U.S. covered lives for its obesity medicines by about 35%, and that roughly 60% to 70% of patients were new incretin starts. CEO Dave Ricks said, "we approximate around 60%-70% being new people that are coming in that have not had access before." Lilly Q2 2026 materials
The early uptake still appears small relative to the potential market. KFF estimated that 3.8 million Medicare Part D enrollees met the clinical and coverage criteria for the Bridge in 2023. KFF estimate
By the numbers
- 700,000 - Lilly's estimate of new seniors who started GLP-1 drugs since July
- 70% - Lilly's estimate of those new seniors who are on its medicines
- 3.8 million - KFF estimate of Medicare Part D enrollees who met Bridge eligibility criteria in 2023
Yes, but: Lilly's 700,000 figure and 70% share are company-reported and the exact methodology is unclear from the materials provided.
What's next: The Medicare GLP-1 Bridge runs through December 31, 2027.